BBIO: the balance sheet

MyFinsight

For the year ending 2025-12-31, BBIO has $936,025K in assets. $3,012,606K in debts. $570,119K in cash and cash equivalents.

Balance Sheets Overview

Current Ratio
277.02%
Quick Ratio
267.73%
Cash Ratio
197.98%
Debt to Asset Ratio
321.85%
Unit: Thousand (K) dollars
Assets Breakdown
Cash and cash equivalents
Accounts receivable, net
Equity method investments
Others
Liabilities Breakdown
Accumulated deficit
Additional paid-in capital
Carrying value of deferred royal...
Others

Balance Sheets	2025-12-31
Cash and cash equivalents	570,119
Marketable securities	17,363
Accounts receivable, net	139,444
Inventories	26,753
Prepaid expenses and other current assets	44,070
Total current assets	797,749
Equity method investments	79,972
Property and equipment, net	5,366
Operating lease right-of-use assets	8,149
Intangible assets, net	28,077
Other assets	16,712
Total assets	936,025

Accounts payable	36,228
Accrued compensation and benefits	76,703
Accrued research and development liabilities	41,436
Operating lease liabilities, current portion	6,192
Deferred revenue, current portion	7,190
Other current liabilities	120,222
Total current liabilities	287,971
2031 notes, 2029 notes, 2027 notes, and term loan, net-A2031Convertible Senior Notes	564,565
2031 notes, 2029 notes, 2027 notes, and term loan, net-A2029Convertible Senior Notes	740,890
2031 notes, 2029 notes, 2027 notes, and term loan, net-A2027Convertible Senior Notes	547,015
2031 notes, 2029 notes, 2027 notes, and term loan, net-Term Loan	0
Carrying value of deferred royalty obligations, net	891,388
Funding Agreement	21,439
Royalty Purchase Agreement	0
Fair value of embedded derivative liability	21,439
Unamortized debt discount and issuance costs	57,797
Deferred royalty obligations, net	855,030
Operating lease liabilities, net of current portion	3,811
Deferred revenue, net of current portion	13,080
Other long-term liabilities	244
Total liabilities	3,012,606
Redeemable convertible noncontrolling interests	-570
Common stock, 0.001 par value 500,000,000 shares authorized 198,759,831 shares issued and 192,633,286 shares outstanding as of december 31, 2025, 196,236,234 shares issued and 190,044,473 shares outstanding as of december 31, 2024	202
Treasury stock, at cost 7,597,172 shares as of december 31, 2025 6,191,761 shares as of december 31, 2024	323,276
Additional paid-in capital	2,057,646
Accumulated other comprehensive income	12
Accumulated deficit	-3,821,194
Total bridgebio stockholders deficit	-2,086,610
Noncontrolling interests	10,599
Total stockholders deficit	-2,076,011
Total liabilities, redeemable convertible noncontrolling interests and stockholders deficit	936,025

Unit: Thousand (K) dollars (except for numbers of shares and EPS).

MyFinsight

Balance Sheets Overview

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Balance Sheets Overview

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets